Cargando…
A Randomized Controlled Trial of Norepinephrine Plus Dobutamine Versus Epinephrine As First-Line Vasoactive Agents in Children With Fluid Refractory Cold Septic Shock
Our objective was to compare norepinephrine plus dobutamine versus epinephrine as the first-line agent in children with fluid refractory cold septic shock. DESIGN: Open-label randomized controlled study. SETTING: A single-center PICU from North India. PATIENTS: Children 2 months to less than 18 year...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9799172/ https://www.ncbi.nlm.nih.gov/pubmed/36600781 http://dx.doi.org/10.1097/CCE.0000000000000815 |
_version_ | 1784861054738628608 |
---|---|
author | Banothu, Kiran Kumar Sankar, Jhuma Kumar, U. Vijaya Gupta, Priyanka Pathak, Mona Jat, Kana Ram Kabra, Sushil Kumar Lodha, Rakesh |
author_facet | Banothu, Kiran Kumar Sankar, Jhuma Kumar, U. Vijaya Gupta, Priyanka Pathak, Mona Jat, Kana Ram Kabra, Sushil Kumar Lodha, Rakesh |
author_sort | Banothu, Kiran Kumar |
collection | PubMed |
description | Our objective was to compare norepinephrine plus dobutamine versus epinephrine as the first-line agent in children with fluid refractory cold septic shock. DESIGN: Open-label randomized controlled study. SETTING: A single-center PICU from North India. PATIENTS: Children 2 months to less than 18 years old with fluid refractory cold septic shock. INTERVENTIONS: In the intervention group, norepinephrine and dobutamine were started and in the control group, epinephrine was started as the first-line vasoactive agent. The primary outcome was the proportion attaining shock resolution (attaining all the therapeutic endpoints) at 1 hour of therapy. MEASUREMENTS AND MAIN RESULTS: We enrolled 67 children: 34 in the norepinephrine plus dobutamine group (intervention) and 33 in the epinephrine group (control). There was no difference in shock resolution at 1 hour (17.6% vs 9%; risk ratio [RR], 2.0; 95% CI, 0.54–7.35; p = 0.25), 6 hours (76.4% vs 54.5%; RR, 1.69; 95% CI, 0.92–3.13; p = 0.06), and 24 hours between the intervention and control groups, respectively. Children in the norepinephrine plus dobutamine group attained shock resolution earlier (measured from starting of vasoactive agents to attaining all the therapeutic endpoints) (hazard ratio, 1.84 [1.1–3.08]). The difference in 28-day mortality was not significant (23.5% vs 39.3% in the intervention and control groups, respectively [RR, 0.59; 95% CI, 0.28–1.25]). CONCLUSIONS: In children with fluid refractory cold septic shock, with use of norepinephrine plus dobutamine as first-line agents, the difference in the proportion of children attaining shock resolution at 1 hour between the groups was inconclusive. However, the time to shock resolution was earlier in the norepinephrine plus dobutamine group. Also, fewer children in the intervention group were refractory to treatment. Further studies powered to detect (or exclude) an important difference would be required to test this intervention. |
format | Online Article Text |
id | pubmed-9799172 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-97991722023-01-03 A Randomized Controlled Trial of Norepinephrine Plus Dobutamine Versus Epinephrine As First-Line Vasoactive Agents in Children With Fluid Refractory Cold Septic Shock Banothu, Kiran Kumar Sankar, Jhuma Kumar, U. Vijaya Gupta, Priyanka Pathak, Mona Jat, Kana Ram Kabra, Sushil Kumar Lodha, Rakesh Crit Care Explor Original Clinical Report Our objective was to compare norepinephrine plus dobutamine versus epinephrine as the first-line agent in children with fluid refractory cold septic shock. DESIGN: Open-label randomized controlled study. SETTING: A single-center PICU from North India. PATIENTS: Children 2 months to less than 18 years old with fluid refractory cold septic shock. INTERVENTIONS: In the intervention group, norepinephrine and dobutamine were started and in the control group, epinephrine was started as the first-line vasoactive agent. The primary outcome was the proportion attaining shock resolution (attaining all the therapeutic endpoints) at 1 hour of therapy. MEASUREMENTS AND MAIN RESULTS: We enrolled 67 children: 34 in the norepinephrine plus dobutamine group (intervention) and 33 in the epinephrine group (control). There was no difference in shock resolution at 1 hour (17.6% vs 9%; risk ratio [RR], 2.0; 95% CI, 0.54–7.35; p = 0.25), 6 hours (76.4% vs 54.5%; RR, 1.69; 95% CI, 0.92–3.13; p = 0.06), and 24 hours between the intervention and control groups, respectively. Children in the norepinephrine plus dobutamine group attained shock resolution earlier (measured from starting of vasoactive agents to attaining all the therapeutic endpoints) (hazard ratio, 1.84 [1.1–3.08]). The difference in 28-day mortality was not significant (23.5% vs 39.3% in the intervention and control groups, respectively [RR, 0.59; 95% CI, 0.28–1.25]). CONCLUSIONS: In children with fluid refractory cold septic shock, with use of norepinephrine plus dobutamine as first-line agents, the difference in the proportion of children attaining shock resolution at 1 hour between the groups was inconclusive. However, the time to shock resolution was earlier in the norepinephrine plus dobutamine group. Also, fewer children in the intervention group were refractory to treatment. Further studies powered to detect (or exclude) an important difference would be required to test this intervention. Lippincott Williams & Wilkins 2022-12-28 /pmc/articles/PMC9799172/ /pubmed/36600781 http://dx.doi.org/10.1097/CCE.0000000000000815 Text en Copyright © 2022 The Authors. Published by Wolters Kluwer Health, Inc. on behalf of the Society of Critical Care Medicine. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. |
spellingShingle | Original Clinical Report Banothu, Kiran Kumar Sankar, Jhuma Kumar, U. Vijaya Gupta, Priyanka Pathak, Mona Jat, Kana Ram Kabra, Sushil Kumar Lodha, Rakesh A Randomized Controlled Trial of Norepinephrine Plus Dobutamine Versus Epinephrine As First-Line Vasoactive Agents in Children With Fluid Refractory Cold Septic Shock |
title | A Randomized Controlled Trial of Norepinephrine Plus Dobutamine Versus Epinephrine As First-Line Vasoactive Agents in Children With Fluid Refractory Cold Septic Shock |
title_full | A Randomized Controlled Trial of Norepinephrine Plus Dobutamine Versus Epinephrine As First-Line Vasoactive Agents in Children With Fluid Refractory Cold Septic Shock |
title_fullStr | A Randomized Controlled Trial of Norepinephrine Plus Dobutamine Versus Epinephrine As First-Line Vasoactive Agents in Children With Fluid Refractory Cold Septic Shock |
title_full_unstemmed | A Randomized Controlled Trial of Norepinephrine Plus Dobutamine Versus Epinephrine As First-Line Vasoactive Agents in Children With Fluid Refractory Cold Septic Shock |
title_short | A Randomized Controlled Trial of Norepinephrine Plus Dobutamine Versus Epinephrine As First-Line Vasoactive Agents in Children With Fluid Refractory Cold Septic Shock |
title_sort | randomized controlled trial of norepinephrine plus dobutamine versus epinephrine as first-line vasoactive agents in children with fluid refractory cold septic shock |
topic | Original Clinical Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9799172/ https://www.ncbi.nlm.nih.gov/pubmed/36600781 http://dx.doi.org/10.1097/CCE.0000000000000815 |
work_keys_str_mv | AT banothukirankumar arandomizedcontrolledtrialofnorepinephrineplusdobutamineversusepinephrineasfirstlinevasoactiveagentsinchildrenwithfluidrefractorycoldsepticshock AT sankarjhuma arandomizedcontrolledtrialofnorepinephrineplusdobutamineversusepinephrineasfirstlinevasoactiveagentsinchildrenwithfluidrefractorycoldsepticshock AT kumaruvijaya arandomizedcontrolledtrialofnorepinephrineplusdobutamineversusepinephrineasfirstlinevasoactiveagentsinchildrenwithfluidrefractorycoldsepticshock AT guptapriyanka arandomizedcontrolledtrialofnorepinephrineplusdobutamineversusepinephrineasfirstlinevasoactiveagentsinchildrenwithfluidrefractorycoldsepticshock AT pathakmona arandomizedcontrolledtrialofnorepinephrineplusdobutamineversusepinephrineasfirstlinevasoactiveagentsinchildrenwithfluidrefractorycoldsepticshock AT jatkanaram arandomizedcontrolledtrialofnorepinephrineplusdobutamineversusepinephrineasfirstlinevasoactiveagentsinchildrenwithfluidrefractorycoldsepticshock AT kabrasushilkumar arandomizedcontrolledtrialofnorepinephrineplusdobutamineversusepinephrineasfirstlinevasoactiveagentsinchildrenwithfluidrefractorycoldsepticshock AT lodharakesh arandomizedcontrolledtrialofnorepinephrineplusdobutamineversusepinephrineasfirstlinevasoactiveagentsinchildrenwithfluidrefractorycoldsepticshock AT banothukirankumar randomizedcontrolledtrialofnorepinephrineplusdobutamineversusepinephrineasfirstlinevasoactiveagentsinchildrenwithfluidrefractorycoldsepticshock AT sankarjhuma randomizedcontrolledtrialofnorepinephrineplusdobutamineversusepinephrineasfirstlinevasoactiveagentsinchildrenwithfluidrefractorycoldsepticshock AT kumaruvijaya randomizedcontrolledtrialofnorepinephrineplusdobutamineversusepinephrineasfirstlinevasoactiveagentsinchildrenwithfluidrefractorycoldsepticshock AT guptapriyanka randomizedcontrolledtrialofnorepinephrineplusdobutamineversusepinephrineasfirstlinevasoactiveagentsinchildrenwithfluidrefractorycoldsepticshock AT pathakmona randomizedcontrolledtrialofnorepinephrineplusdobutamineversusepinephrineasfirstlinevasoactiveagentsinchildrenwithfluidrefractorycoldsepticshock AT jatkanaram randomizedcontrolledtrialofnorepinephrineplusdobutamineversusepinephrineasfirstlinevasoactiveagentsinchildrenwithfluidrefractorycoldsepticshock AT kabrasushilkumar randomizedcontrolledtrialofnorepinephrineplusdobutamineversusepinephrineasfirstlinevasoactiveagentsinchildrenwithfluidrefractorycoldsepticshock AT lodharakesh randomizedcontrolledtrialofnorepinephrineplusdobutamineversusepinephrineasfirstlinevasoactiveagentsinchildrenwithfluidrefractorycoldsepticshock |